- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004334
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease.
II. Identify subgroups of patients with Cushing's disease who differ in the presence and severity of the depressive syndrome, and uncover HPA axis dysregulation differences among them using corticotropin-releasing hormone, metyrapone, and dexamethasone challenge testing.
Study Overview
Status
Conditions
Detailed Description
PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol, and urinary cortisol. Peptide and steroid assays are performed, alone and in response to corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep electroencephalograms at baseline and 1 year following treatment.
A weight maintenance diet is prescribed for all patients.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Health Systems
-
Contact:
- Monica N. Starkman
- Phone Number: 313-764-6168
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
- Patients aged 20 to 60 with spontaneous active Cushing's syndrome
- At least 2 weeks since medication with psychoactive effects or influence on cortisol metabolism by hepatic hydroxylating enzyme induction
- Antihypertensives allowed for severe hypertension
- No barbiturates
- No phenytoin
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Monica N. Starkman, University of Michigan
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCRR-M01RR00042-1781
- UMMC-701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing's Syndrome
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
Corcept TherapeuticsCompleted
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain
-
Wuerzburg University HospitalCompletedEndogenous Cushing's SyndromeGermany
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Serbia, Denmark, Italy, Spain, Poland, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Netherlands, Turkey
-
Andrea M. IsidoriCompletedCushing's Syndrome CardiomyopathyItaly
-
Sparrow PharmaceuticalsRecruitingAutonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, SomaticUnited States, United Kingdom, France, Romania
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted
-
University Hospital, Clermont-FerrandUnité de recherche GReD CNRS UMR6293 / InsermRecruitingOsteoporosis in Cushing's Syndrome | Osteoporosis in Post-menopausal WomenFrance
-
HRA PharmaCompletedCushing's SyndromeGermany, Belgium, Italy, Hungary, Poland, Romania, Spain, Turkey